文献速递炎症性肠病

乌司奴单抗治疗中重度溃疡性结肠炎的有效性:加拿大 multicenter 真实世界研究

Effectiveness of Ustekinumab for Patients With Moderate-to-Severe Ulcerative Colitis: A Multicenter Real-World Canadian Study.
PubMed 文献 · Am J Gastroenterol · 2024-11-14

这项加拿大回顾性多中心队列研究纳入198例中重度溃疡性结肠炎患者,其中88.8%有生物制剂暴露史。乌司奴单抗治疗12个月临床缓解率为43.6%,内镜缓解率12.5%,生物制剂初治患者内镜缓解率持续高于经治患者,不良事件发生率14.1%。

要点

  • 乌司奴单抗治疗12个月临床缓解率43.6%(58/133),内镜缓解率12.5%(11/88)。
  • 生物制剂初治患者内镜缓解率在各时间点均高于经治患者(P<0.05)。
  • 生物制剂初治患者达到内镜缓解的可能性更高(HR=5.40,95%CI:1.08-26.93)。

核心结论

  • 在高度难治且大部分有生物制剂暴露史的人群中,相当比例溃疡性结肠炎患者接受乌司奴单抗治疗12个月后可获得重要的临床和内镜结局。
  • 既往生物制剂暴露与较低的内镜缓解率相关。

研究设计与样本

  • 回顾性、加拿大 multicenter 队列研究。
  • 共纳入198例溃疡性结肠炎患者,其中女性47.5%,85.9%年龄小于65岁。
  • 基线时47.5%(n=87)有严重内镜活动,88.8%(n=176)有生物制剂暴露史,33%(n=66)既往失败3种或以上生物制剂。
  • 诱导后中位随访12.8个月(四分位距8.2-22.1)。
  • 主要结局为临床缓解和内镜缓解;关键次要结局包括复合临床和内镜应答、安全性和持续性。

主要发现

  • 总体临床缓解率在3、6、12个月分别为41.3%(69/167)、38.1%(56/147)、43.6%(58/133)。
  • 内镜缓解率(Mayo内镜评分=0)在3、6、12个月分别为8.0%(7/88)、18.7%(23/123)、12.5%(11/88),且直至12个月生物制剂初治患者持续高于经治患者(所有时间点P<0.05)。
  • 生物制剂初治患者较经治患者更可能达到内镜缓解(HR=5.40,95%CI:1.08-26.93)。
  • 不良事件报告率为14.1%(18/198)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: We aimed to evaluate the real-world effectiveness and safety of ustekinumab for the treatment of both bio-naive and bio-exposed ulcerative colitis patients in a real-world setting. METHODS: Retrospective, Canadian multicenter cohort study. Primary outcomes were clinical remission and endoscopic remission. Key secondary outcomes included composite clinical and endoscopic response, safety, and persistence. Univariable logistic regression was conducted to examine associations between baseline factors and 12-month clinical and endoscopic response and remission. The primary focus was on the association between these outcomes and bioexposure status. RESULTS: A total of 198 patients were included, of whom 47.5% were female and 85.9% were younger than 65 years. The majority had severe endoscopic activity at baseline (47.5%, n = 87) and were bio-exposed (88.8%, n = 176; 33%, n = 66 previous failure of 3 or more biologics). Patients were followed for a median of 12.8 (interquartile range 8.2-22.1) months after induction. The overall clinical remission rates were 41.3% (69/167), 38.1% (56/147), and 43.6% (58/133) at 3, 6 and 12 months, respectively. Endoscopic remission rates (Mayo endoscopy score = 0) were 8.0% (7/88), 18.7% (23/123), and 12.5% (11/88) at 3, 6, and 12 months, respectively, and consistently higher in bio-naive patients compared with bio-exposed patients through 12 months ( P < 0.05 at all time points). Bio-naive patients were more likely to achieve endoscopic remission compared with bio-exposed (hazard ratio = 5.40, 95% confidence interval [CI]: 1.08-26.93). Adverse events were reported in 14.1% (18/198). DISCUSSION: In a highly refractory and largely bio-exposed population, a substantial proportion of patients with ulcerative colitis treated with ustekinumab can achieve clinical and endoscopic outcomes of importance after 12 months. Previous biologic exposure is associated with lower rates of endoscopic remission.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Solitano V, Narula N, Ma C, et al. Effectiveness of Ustekinumab for Patients With Moderate-to-Severe Ulcerative Colitis: A Multicenter Real-World Canadian Study. Am J Gastroenterol. 2024. PMID: 39657015. doi:10.14309/ajg.0000000000003212

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。